Summary

The 7 major polymyalgia rheumatica markets reached a value of US$ 3,287.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12,677.8 Million by 2034, exhibiting a growth rate (CAGR) of 13.06% during 2024-2034.

The polymyalgia rheumatica market has been comprehensively analyzed in IMARC's new report titled "Polymyalgia Rheumatica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polymyalgia rheumatica refers to an inflammatory condition that causes muscle stiffness and pain, especially in the hips and shoulders. The common symptoms of this ailment include mild fever, fatigue, a general feeling of not being well, lack of appetite, unintended weight loss, depression, etc. Individuals suffering from polymyalgia rheumatica may also experience several indications, such as aches in the neck, upper arms, buttocks, or thighs, stiffness in the affected regions, particularly after being inactive for a time or in the morning, limited range of motion, etc. The diagnosis of this disease is based on a review of the patient’s symptoms, medical history, and physical examination. Numerous blood tests, including complete blood count (CBC), C-reactive protein, erythrocyte sedimentation rate, etc., are also utilized to confirm a diagnosis. The healthcare provider may perform several imaging studies, including MRI and ultrasound, for the evaluation of underlying indications.

The rising prevalence of several risk factors, such as genetic predisposition, chronic infections, environmental aspects, etc., is primarily driving the polymyalgia rheumatica market. In addition to this, the expanding geriatric population, who are more prone to immune dysfunction due to the reduced ability of producing new T cells, is also bolstering the market growth. Moreover, the widespread adoption of effective corticosteroids, including prednisolone which blocks the effects of specific chemicals in the body to decrease inflammation and enhance tissue growth and repair, is creating a positive outlook for the market. Apart from this, the inflating application of physical therapy to improve strength and increase the range of motion in patients is further propelling the market growth. Additionally, various key players are investing in extensive R&D activities to launch novel regimens that promote muscle flexibility and offer better bone health. This, in turn, is also acting as another significant growth-inducing factor. Moreover, the emerging popularity of subcutaneous sarilumab injection in disease treatment, since it works by blocking the interleukin-6 activity, a substance that causes inflammation in the body, is expected to drive the polymyalgia rheumatica market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the polymyalgia rheumatica market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polymyalgia rheumatica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polymyalgia rheumatica market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polymyalgia rheumatica market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polymyalgia rheumatica market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polymyalgia rheumatica marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the polymyalgia rheumatica market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polymyalgia rheumatica market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polymyalgia rheumatica market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with polymyalgia rheumatica across the seven major markets?
What is the size of the polymyalgia rheumatica patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polymyalgia rheumatica?
What will be the growth rate of patients across the seven major markets?

Polymyalgia Rheumatica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polymyalgia rheumatica drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polymyalgia rheumatica market?
What are the key regulatory events related to the polymyalgia rheumatica market?
What is the structure of clinical trial landscape by status related to the polymyalgia rheumatica market?
What is the structure of clinical trial landscape by phase related to the polymyalgia rheumatica market?
What is the structure of clinical trial landscape by route of administration related to the polymyalgia rheumatica market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Polymyalgia Rheumatica - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Polymyalgia Rheumatica - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Polymyalgia Rheumatica - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Polymyalgia Rheumatica - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Polymyalgia Rheumatica - Unmet Needs

10 Polymyalgia Rheumatica - Key Endpoints of Treatment

11 Polymyalgia Rheumatica - Marketed Products
11.1 List of Polymyalgia Rheumatica Marketed Drugs Across the Top 7 Markets
11.1.1 Rayos (Prednisone controlled-release) - Horizon Pharma/Vectura
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Polymyalgia Rheumatica - Pipeline Drugs
12.1 List of Polymyalgia Rheumatica Pipeline Drugs Across the Top 7 Markets
12.1.1 ABBV154 - AbbVie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SPI 62 - Sparrow Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tocilizumab - Chugai Pharmaceutical/Roche
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Abatacept - Bristol-Myers Squibb
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Baricitinib - Eli Lilly and Company/Incyte Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Polymyalgia Rheumatica - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Polymyalgia Rheumatica – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Polymyalgia Rheumatica - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polymyalgia Rheumatica - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polymyalgia Rheumatica - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polymyalgia Rheumatica - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polymyalgia Rheumatica - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polymyalgia Rheumatica - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polymyalgia Rheumatica - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polymyalgia Rheumatica - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polymyalgia Rheumatica - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polymyalgia Rheumatica - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polymyalgia Rheumatica - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polymyalgia Rheumatica - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polymyalgia Rheumatica - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polymyalgia Rheumatica - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polymyalgia Rheumatica - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polymyalgia Rheumatica - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polymyalgia Rheumatica - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polymyalgia Rheumatica - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polymyalgia Rheumatica - Access and Reimbursement Overview

16 Polymyalgia Rheumatica - Recent Events and Inputs From Key Opinion Leaders

17 Polymyalgia Rheumatica Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Polymyalgia Rheumatica Market – Strategic Recommendations

19 Appendix